Evogene stock falls to USD 0.50 after board turmoil

Published on 09/20/2026 at 18:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evogene stock closed at USD 0.50 on September 18, 2026, with market value at USD 4.35 million. MarketBeat says the last quarter brought USD 0.33 million in revenue and an EPS loss of USD 0.60.

EVGN, IL0010831684, Illustration mit AI erstellt.

Evogene Ltd. (IL0010831684) stock closed at USD 0.50 on September 18, 2026, with a market capitalization of USD 4.35 million and volume of 17,975 shares. The move came as the stock stayed near the low end of its 52-week range of USD 0.37 to USD 1.50.

Board dispute stays in view

MarketBeat's EVGN page still shows a sell consensus and a single sell-side report over the past 90 days, while its news feed points to dissident shareholder pressure after the September AGM and board resignations on September 15, 2026. That keeps governance, not operations alone, in the spotlight for investors.

MarketBeat also says Evogene last reported quarterly earnings on May 16, 2026, with revenue of USD 0.33 million and EPS of USD -0.60, compared with analyst estimates of USD 0.35 million and EPS of USD -0.27. The miss was USD 0.33 per share and revenue trailed estimates by USD 0.02 million.

Losses remain heavy

The same page puts trailing-twelve-month EPS at USD -0.91, net income at USD -8.48 million and net margin at -694.18 percent, all signs that the current valuation is still tied to a very weak earnings base. MarketBeat also lists short interest at 0.66 percent of the float, down 77.16 percent from the previous month.

Stock near the bottom

Evogene stock traded at USD 0.50 on September 18, 2026, after a year-to-date slide of 54.6 percent from USD 1.10 at the start of 2026. The 50-day range is USD 0.46 to USD 0.70, so the shares are still trading close to the lower end of their recent band.